drugset / Trial / NCT05327114

Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT05327114 ↗

Phase 2/3 Recruiting 201 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The main purpose of this study is to evaluate the safety and efficacy of nipocalimab compared to placebo in delaying relapse in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) who initially respond to nipocalimab in Stage A.

Timeline

Start
2022-09-23
Primary completion
2027-05-14
Completion
2028-11-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Nipocalimab Monoclonal antibody — Intravenous